Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | Breast Cancer Research

Figure 5

From: Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

Figure 5

Pharmacokinetics in cynomolgus monkeys. Serum concentration-versus-time profiles for intravenous administration of MGAH22 or RES120 at a single 50 mg/kg dose (a) or MGAH22 at 15 (b), 50 (c), or 150 (d) mg/kg weekly for 6 weeks. Data are presented as mean ± standard error of the mean. MGAH22, chimeric anti-HER2 monoclonal antibody with an optimized Fc domain; RES120, chimeric anti-HER2 monoclonal antibody with wild-type human immunoglobulin G 1 Fc domain.

Back to article page